The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil

Rossi, Flávia; Cury, Arlete Emily; Franco, Maria Renata Gomes; Testa, R. T.; Nichols, Wright W.

doi:10.1016/j.bjid.2017.03.008

Cited by 15 publications

(11 citation statements)

References 6 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differences in CZA susceptibility of the non-susceptible subgroups could be explained by the different hospitals and geographical areas included in the study, as well as the changes in the epidemiology of resistance mechanisms between the study periods. For example, in the case of Brazil, susceptibility rates to CZA in this study were inferior to those observed previously against K. pneumoniae isolates in a surveillance study by Rossi et al (100% susceptible) [10]. An increase in class B β-lactamases (which were detected in 0.2% of all Enterobacterales by Karlowsky et al) or the emergence of different mechanisms of resistance to CZA in class A β-lactamase-producing K. pneumoniae as reported in the literature could explain this difference [11,12].…”

Section: Discussioncontrasting

confidence: 99%

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

et al. 2020

View full text Add to dashboard Cite

Background: High rates of resistance to third-generation cephalosporins and carbapenems in Enterobacterales have been reported in Latin America. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam β-lactamase inhibitor, which has shown activity against isolates producing class A, C and D β-lactamases. Herein, we evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales in Latin America. Methods: The activity of CZA and comparators was evaluated against clinical isolates of Enterobacterales from Argentina, Brazil, Chile, Colombia and Mexico that were collected between January 2016 and October 2017. One specific phenotypic subset was evaluated. A carbapenem non-susceptible (CNS) phenotype was defined as any isolate displaying a minimum inhibitory concentration (MIC) ≥1 mg/L for ertapenem. Results: CZA was active against 95.8% of all isolates and 77.5% of CNS isolates. Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales being susceptible. Conclusions: The results of this study underline the potential therapeutic role of CZA in Latin America.

show abstract

Section: Discussioncontrasting

confidence: 99%

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In the current study, we also noted that 87.4% of all isolates of P. aeruginosa tested were susceptible to ceftazidime-avibactam, with an MIC 90 of 16 g/ml (Table 1). Our results confirm earlier observations made regarding clinical isolates of P. aeruginosa from Latin American laboratories (2,4,6). Rossi (6).…”

Section: Discussionsupporting

confidence: 92%

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Karlowsky¹,

Kazmierczak²,

Bouchillon³

et al. 2019

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The International Network for Optimal Resistance Monitoring (INFORM) global surveillance program collected clinical isolates of Enterobacteriaceae (n ϭ 7,665) and Pseudomonas aeruginosa (n ϭ 1,794) from 26 medical centers in six Latin American countries from 2012 to 2015. The in vitro activity of ceftazidime-avibactam and comparators was determined for the isolates using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method. Enterobacteriaceae were highly susceptible (99.7%) to ceftazidime-avibactam, including 99.9% of metallo-␤-lactamase (MBL)-negative isolates; 87.4% of all P. aeruginosa isolates and 92.8% of MBL-negative isolates were susceptible to ceftazidime-avibactam. Susceptibility to ceftazidime-avibactam ranged from 99.4% to 100% for Enterobacteriaceae and from 79.1% to 94.7% for P. aeruginosa when isolates were analyzed by country of origin. Ceftazidime-avibactam inhibited 99.6% to 100% of Enterobacteriaceae isolates that carried serine ␤-lactamases, including extended-spectrum ␤-lactamases (ESBLs), AmpC cephalosporinases, and carbapenemases (KPC and OXA-48-like) as well as 99.7%, 99.6%, 99.5%, and 99.2% of MBL-negative isolatesdemonstratingceftazidime-nonsusceptible,multidrug-resistant(MDR),meropenem-nonsusceptible, and colistin-resistant phenotypes, respectively. Among carbapenem-nonsusceptible isolates of P. aeruginosa (n ϭ 750), 14.7% carried MBLs with or without additional acquired serine ␤-lactamases, while in the majority of isolates (70.0%), no acquired ␤-lactamase was identified. Ceftazidime-avibactam inhibited 89.5% of carbapenem-nonsusceptible P. aeruginosa isolates in which no acquired ␤-lactamase was detected. Overall, clinical isolates of Enterobacteriaceae collected in Latin America from 2012 to 2015 were highly susceptible to ceftazidime-avibactam, including isolates that exhibited resistance to ceftazidime, meropenem, colistin, or an MDR phenotype. Country-specific variations were noted in the susceptibility of P. aeruginosa isolates to ceftazidime-avibactam.

show abstract

“…Internationally for example, the 60% resistance rate detected among our CR E. coli isolates was lower than reported from China (71%) [16]. However, the 65% resistant rate detected among our CR K. pneumoniae isolates was far higher than those reported from USA (0-21%) [17,11,12], China (15%) [16] and Brazil (3%) [18].…”

Section: Discussioncontrasting

confidence: 66%

Emerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon

Sobh

Karaaoui

Chaar

et al. 2021

int. arab. j antimicrob. agents

View full text Add to dashboard Cite

show abstract

The in vitro activity of ceftazidime–avibactam against 417 Gram-negative bacilli collected in 2014 and 2015 at a teaching hospital in São Paulo, Brazil

Cited by 15 publications

References 6 publications

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

In Vitro Susceptibility to Ceftazidime/Avibactam and Comparators in Clinical Isolates of Enterobacterales from Five Latin American Countries

In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015

Emerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon

Contact Info

Product

Resources

About